Immunohematology Market
完整報告名稱與涵蓋範圍
Immunohematology Market Research Report by Product (Reagents, Instruments / Analyzers, and Consumables & Accessories), by Application (Blood Related Disorders, HIV), by End User (Hospitals, Diagnostic Laboratories, and Blood Banks), by Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) Forecast till 2035
報告摘要
The Global Immunohematology Market was valued at USD 1,810.36 million in 2025 and is projected to reach USD 2,711.24 million by 2035. The market is expected to expand at a CAGR of 4.3% during the forecast period, driven by the growing demand for blood screening, transfusion safety, and advanced diagnostic technologies.
Growing Adoption of Automated Immunohematology Analysers Drives Market Expansion
The enhanced yield of the global immunohematology market is majorly attributed to the increasing installation of automated immunohematology analysers as laboratories opt for rapid, accurate, blood typing, and compatibility testing solutions. Automation reduces human error, improves laboratory efficiency, and enables high-volume testing, helping healthcare facilities meet the rising demand for safe blood transfusion services.
Market Segmentation Snapshot
By Product
• Reagents: Essential for accurate blood grouping and compatibility testing.
• Instruments / Analyzers: Enable automated, high-throughput immunohematology testing workflows.
• Consumables & Accessories: Support routine laboratory operations and testing procedures.
By Application
• Blood Related Disorders: Facilitate diagnosis and management of hematological conditions.
• HIV: Ensure safe transfusion practices through blood screening.
By End User
• Hospitals: Conduct transfusion testing for patient care needs.
• Diagnostic Laboratories: Provide specialized immunohematology testing services.
• Blood Banks: Ensure blood safety, storage, and compatibility.
The North America holds the immunohematology market at the lead globally driven by advanced healthcare systems, the high frequency of blood transfusion, and the wide use of automated testing technologies. On the other hand, Europe has been the most steady performer with strong regulatory frameworks and standardized transfusion practices. Asia Pacific has been the fastest-growing market mainly due to healthcare modernization and rising blood safety awareness. Whilst South America and the Middle East & Africa are gradually expanding the market local improvements in transfusions services and laboratory automation, continuing to be the main stimuli.
Strengthening Blood Screening Through Multiplex Innovation
Recently, the company introduced the cobas® MPX-E assay, This is a 4-in-1 multiplex NAT test of detection of HIV, HBV, HCV, and HEV. Such innovative new blood donor screening methods render most efficient use of the physical and human resources, streamline laboratory operations, and enhance transfusion safety standards.
Accelerating Laboratory Efficiency Through Automation
By switching over to automated high-throughput immunohematology systems, laboratories now have the means to perform large testing volumes at high speed and with great reproducibility. This will raise the level of operational efficiency, reduce the extent of manual work, and allow healthcare providers to cope with the increasing demands for transfusion testing.
Key Report Attributes
• Market Size 2025: USD 1,810.36 Million
• Market Size 2035: USD 2,711.24 Million
• CAGR (2025-2035): 4.3%
• Base Year: 2024
• Market Forecast Period: 2025-2035
Industry Segmentations Growth
• By Product: Reagents - 3.8%, Instruments / Analyzers - 5.3%.
• By Application: Blood Related Disorders - 4.8%, HIV - 3.0%.
• By End User: Hospitals - 3.3%, Diagnostic Laboratories - 4.8%.
授權報價
| Single User Price | $4,950 USD |
| Multi User Licence (up to 10 users) | $5,950 USD |
| Enterprisewide Price (Global Site License) | $7,250 USD |
目錄 Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ..... 16
2 MARKET INTRODUCTION ....................................................... 18
2.1 DEFINITION ........................................................ 18
2.2 SCOPE OF THE STUDY .................................... 18
2.3 RESEARCH OBJECTIVE .................................. 18
2.4 MARKET STRUCTURE .................................... 19
3 RESEARCH METHODOLOGY ................................................. 20
3.1 OVERVIEW ..... 20
3.2 DATA FLOW ........................................................ 22
3.2.1 DATA MINING PROCESS ............................. 22
3.3 PURCHASED DATABASE: ............................... 23
3.4 SECONDARY SOURCES: .................................. 24
3.4.1 SECONDARY RESEARCH DATA FLOW: ............. 25
3.5 PRIMARY RESEARCH: ..................................... 26
3.5.1 PRIMARY RESEARCH DATA FLOW: ................ 27
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ................................... 28
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ........................................................ 28
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ...................................... 29
3.6.1 REVENUE ANALYSIS APPROACH .................. 29
3.7 DATA FORECASTING....................................... 29
3.7.1 DATA FORECASTING TYPE .......................... 30
3.8 DATA MODELING .............................................. 31
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ............ 31
3.8.2 DATA MODELING: ..................................... 32
3.9 TEAMS AND ANALYST CONTRIBUTION ...................................................... 34
4 MARKET DYNAMICS .......... 36
4.1 INTRODUCTION ................................................. 36
4.2 DRIVERS .......... 37
4.2.1 RISING PREVALENCE OF BLOOD DISORDERS AND CHRONIC DISEASES ........................ 37
4.2.2 AUTOMATION AND TECHNOLOGICAL ADVANCEMENT ............................................. 37
4.2.3 INCREASING BLOOD DONATIONS AND TRANSFUSION PROCEDURES ............................ 38
4.3 RESTRAINTS ...................................................... 39
4.3.1 HIGH COST OF ANALYZERS & REAGENTS ....... 39
4.3.2 CULTURAL STIGMA AND UNDERDIAGNOSIS ...... 39
4.4 OPPORTUNITIES ............................................... 40
4.4.1 GROWTH OF POINT-OF-CARE TESTING (POCT) ...................................................... 40
4.4.2 INCREASING DEMAND FOR AUTOMATED HIGH-THROUGHPUT TESTING SYSTEMS .......... 40
5 MARKET DYNAMICS .......... 41
5.1 VALUE CHAIN ANALYSIS ............................. 41
5.1.1 RAW MATERIAL .................................... 41
5.1.2 MANUFACTURING / PROCESSING ......... 41
5.1.3 PACKAGING ............................................ 42
5.1.4 DISTRIBUTION ...................................... 42
5.1.5 END USER ............................................ 42
5.2 PORTER'S FIVE FORCES MODEL ................. 43
5.2.1 THREAT OF NEW ENTRANTS ......................... 43
5.2.2 BARGAINING POWER OF SUPPLIERS ..... 44
5.2.3 THREAT OF SUBSTITUTES ............................ 44
5.2.4 BARGAINING POWER OF BUYERS .................. 44
5.2.5 INTENSITY OF RIVALRY ................................ 44
6 GLOBAL IMMUNOHEMATOLOGY MARKET, BY PRODUCT ....................................................... 46
6.1 OVERVIEW ..... 46
7 GLOBAL IMMUNOHEMATOLOGY MARKET, BY APPLICATION ................................................. 49
7.1 OVERVIEW ..... 49
8 GLOBAL IMMUNOHEMATOLOGY MARKET, BY END USER ...................................................... 54
8.1 OVERVIEW ..... 54
9 GLOBAL IMMUNOHEMATOLOGY MARKET, BY REGION ..... 56
9.1 OVERVIEW ..... 56
9.2 NORTH AMERICA ............................................. 58
9.2.1 US........................................................ 61
9.2.2 CANADA ................................................ 63
9.3 EUROPE ........... 65
9.3.1 GERMANY .............................................. 68
9.3.2 UK ....................................................... 70
9.3.3 FRANCE ................................................. 72
9.3.4 NETHERLAND ........................................... 74
9.3.5 ITALY ..................................................... 76
9.3.6 SPAIN ................................................... 78
9.3.7 REST OF EUROPE ...................................... 80
9.4 ASIA PACIFIC ..................................................... 82
9.4.1 CHINA ................................................... 85
9.4.2 INDIA .................................................... 87
9.4.3 JAPAN .................................................. 89
9.4.4 SOUTH KOREA ......................................... 91
9.4.5 MALAYSIA .............................................. 93
9.4.6 THAILAND ............................................... 95
9.4.7 INDONESIA ............................................. 97
9.4.8 REST OF ASIA PACIFIC .............................. 99
9.5 SOUTH AMERICA ............................................. 101
9.5.1 BRAZIL ................................................... 105
9.5.2 MEXICO ................................................. 107
9.5.3 ARGENTINA ......................................... 109
9.5.4 REST OF SOUTH AMERICA .......................... 111
9.6 MIDDLE EAST AND AFRICA .......................... 113
9.6.1 GCC COUNTRIES ...................................... 117
9.6.2 SOUTH AFRICA ......................................... 119
9.6.3 REST OF MIDDLE EAST AND AFRICA .............. 121
10 COMPETITIVE LANDSCAPE ................................................... 124
10.1 INTRODUCTION ................................................. 124
10.2 COMPETITOR DASHBOARD........................... 125
10.3 PUBLIC PLAYERS STOCK SUMMARY ....... 126
10.4 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ......................... 126
10.5 KEY DEVELOPMENTS & GROWTH STRATEGIES ....................................... 127
10.5.1 PRODUCT LAUNCH .................................... 127
10.5.2 ACQUISITION ....................................... 127
11 COMPANY MARKET SHARE ANALYSIS, BY COUNTRY, 2025 ................................................... 128
11.1 INTRODUCTION ................................................. 128
11.2 NORTH AMERICA MARKET SHARE ANALYSIS, BY COUNTRY 2025 ....................................................... 130
11.3 EUROPE MARKET SHARE ANALYSIS, BY COUNTRY 2025 ..................... 131
11.4 ASIA PACIFC MARKET SHARE ANALYSIS, BY COUNTRY 2025 ........... 134
11.5 SOUTH AMERICA MARKET SHARE ANALYSIS, BY COUNTRY 2025 ....................................................... 138
11.6 MIDDLE EAST AND AFRICA MARKET SHARE ANALYSIS, BY COUNTRY 2025 ................................... 140
12 COMPANY PROFILES ........ 142
12.1 THERMO FISHER SCIENTIFIC INC. ............. 142
12.1.1 COMPANY OVERVIEW ........................... 142
12.1.2 FINANCIAL OVERVIEW .......................... 143
12.1.3 PRODUCTS OFFERED ............................... 144
12.1.4 KEY DEVELOPMENTS ............................ 144
12.1.5 SWOT ANALYSIS .................................. 145
12.1.6 KEY STRATEGIES .................................. 146
12.2 ABBOTT ........... 147
12.2.1 COMPANY OVERVIEW ........................... 147
12.2.2 FINANCIAL OVERVIEW .......................... 148
12.2.3 PRODUCTS OFFERED ............................ 149
12.2.4 KEY DEVELOPMENTS ............................ 149
12.2.5 SWOT ANALYSIS .................................. 150
12.2.6 KEY STRATEGIES .................................. 151
12.3 MERCK KGAA .................................................... 152
12.3.1 COMPANY OVERVIEW ........................... 152
12.3.2 FINANCIAL OVERVIEW .......................... 153
12.3.3 PRODUCTS OFFERED ................................ 154
12.3.4 KEY DEVELOPMENTS ............................ 154
12.3.5 SWOT ANALYSIS .................................. 155
12.3.6 KEY STRATEGY ......................................... 156
12.4 F. HOFFMANN-LA ROCHE LTD .................... 157
12.4.1 COMPANY OVERVIEW ........................... 157
12.4.2 FINANCIAL OVERVIEW .......................... 158
12.4.4 KEY DEVELOPMENTS ............................ 159
12.4.5 KEY STRATEGIES .................................. 160
12.5 SIEMENS HEALTHINEERS AG ..................... 161
12.5.1 COMPANY OVERVIEW ........................... 161
12.5.2 FINANCIAL OVERVIEW .......................... 162
12.5.3 PRODUCTS OFFERED ............................... 163
12.5.4 KEY DEVELOPMENTS ............................ 163
12.5.5 KEY STRATEGIES .................................. 164
12.6 GRIFOLS, S.A. ...................................................... 165
12.6.1 COMPANY OVERVIEW ........................... 165
12.6.2 FINANCIAL OVERVIEW .......................... 166
12.6.3 PRODUCTS OFFERED ............................... 167
12.6.4 KEY DEVELOPMENTS ............................ 167
12.6.5 SWOT ANALYSIS .................................. 168
12.6.6 KEY STRATEGIES .................................. 169
12.7 BIO-RAD LABORATORIES, INC. .................... 170
12.7.1 COMPANY OVERVIEW ........................... 170
12.7.2 FINANCIAL OVERVIEW .......................... 171
12.7.3 PRODUCTS OFFERED ............................ 172
12.7.4 KEY DEVELOPMENTS ............................ 172
12.7.5 SWOT ANALYSIS .................................. 173
12.7.6 KEY STRATEGIES .................................. 174
12.8 WERFEN ......... 175
12.8.1 COMPANY OVERVIEW ........................... 175
12.8.2 FINANCIAL OVERVIEW .......................... 176
12.8.3 PRODUCTS OFFERED ................................ 176
12.8.4 KEY DEVELOPMENTS ............................ 176
12.8.5 KEY STRATEGY ......................................... 177
12.9 DANAHER CORPORATION ............................. 178
12.9.1 COMPANY OVERVIEW ........................... 178
12.9.2 FINANCIAL OVERVIEW .......................... 179
12.9.4 KEY DEVELOPMENTS ............................ 180
12.9.5 KEY STRATEGIES .................................. 181
12.10 CARDINAL HEALTH......................................... 182
12.10.1 COMPANY OVERVIEW ........................... 182
12.10.2 FINANCIAL OVERVIEW .......................... 183
12.10.3 PRODUCTS OFFERED ............................... 184
12.10.4 KEY DEVELOPMENTS ............................ 184
12.10.5 KEY STRATEGIES .................................. 185
12.11 DATA CITATIONS ............................................. 186
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 33
TABLE 2 GLOBAL IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 47
TABLE 3 GLOBAL IMMUNOHEMATOLOGY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 50
TABLE 4 GLOBAL IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 55
TABLE 5 GLOBAL IMMUNOHEMATOLOGY MARKET, BY REGION, 2019-2035 (USD MILLION) 57
TABLE 6 NORTH AMERICA IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 59
TABLE 7 NORTH AMERICA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 60
TABLE 8 NORTH AMERICA IMMUNOHEMATOLOGY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 60
TABLE 9 NORTH AMERICA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 61
TABLE 10 US IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 61
TABLE 11 US IMMUNOHEMATOLOGY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 61
TABLE 12 US IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 62
TABLE 13 CANADA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 63
TABLE 14 CANADA IMMUNOHEMATOLOGY MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 63
TABLE 15 CANADA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 64
TABLE 16 EUROPE IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 66
TABLE 17 EUROPE IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 67
TABLE 18 EUROPE IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 67
TABLE 19 EUROPE IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 68
TABLE 20 GERMANY IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 68
TABLE 21 GERMANY IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 68
TABLE 22 GERMANY IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 69
TABLE 23 UK IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 70
TABLE 24 UK IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 70
TABLE 25 UK IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 71
TABLE 26 FRANCE IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 72
TABLE 27 FRANCE IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 72
TABLE 28 FRANCE IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 73
TABLE 29 NETHERLAND IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 74
TABLE 30 NETHERLAND IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 74
TABLE 31 NETHERLAND IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 75
TABLE 32 ITALY IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 76
TABLE 33 ITALY IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 76
TABLE 34 ITALY IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 77
TABLE 35 SPAIN IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 78
TABLE 36 SPAIN IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 78
TABLE 37 SPAIN IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 79
TABLE 38 REST OF EUROPE IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 80
TABLE 39 REST OF EUROPE IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 80
TABLE 40 REST OF EUROPE IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 81
TABLE 41 ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 83
Copyright © 2026 Market Research Future 11
TABLE 42 ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 84
TABLE 43 ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 84
TABLE 44 ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 85
TABLE 45 CHINA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 85
TABLE 46 CHINA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 85
TABLE 47 CHINA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 86
TABLE 48 INDIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 87
TABLE 49 INDIA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 87
TABLE 50 INDIA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 88
TABLE 51 JAPAN IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 89
TABLE 52 JAPAN IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 89
TABLE 53 JAPAN IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 90
TABLE 54 SOUTH KOREA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 91
TABLE 55 SOUTH KOREA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 91
TABLE 56 SOUTH KOREA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 92
TABLE 57 MALAYSIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 93
TABLE 58 MALAYSIA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 93
TABLE 59 MALAYSIA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 94
TABLE 60 THAILAND IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 95
TABLE 61 THAILAND IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 95
TABLE 62 THAILAND IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 96
TABLE 63 INDONESIA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 97
TABLE 64 INDONESIA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 97
TABLE 65 INDONESIA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 98
TABLE 66 REST OF ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 99
TABLE 67 REST OF ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 99
TABLE 68 REST OF ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 100
TABLE 69 SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 102
TABLE 70 SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 103
TABLE 71 SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 103
TABLE 72 SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 104
TABLE 73 BRAZIL IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 105
TABLE 74 BRAZIL IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 105
TABLE 75 BRAZIL IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 106
TABLE 76 MEXICO IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 107
TABLE 77 MEXICO IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 107
TABLE 78 MEXICO IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 108
TABLE 79 ARGENTINA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 109
TABLE 80 ARGENTINA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 109
TABLE 81 ARGENTINA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 110
TABLE 82 REST OF SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 111
TABLE 83 REST OF SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 111
TABLE 84 REST OF SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 112
TABLE 85 MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 114
Copyright © 2026 Market Research Future 12
TABLE 86 MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 115
TABLE 87 MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 115
TABLE 88 MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 116
TABLE 89 GCC COUNTRIES IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 117
TABLE 90 GCC COUNTRIES IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 117
TABLE 91 GCC COUNTRIES IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 118
TABLE 92 SOUTH AFRICA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 119
TABLE 93 SOUTH AFRICA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 119
TABLE 94 SOUTH AFRICA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 120
TABLE 95 REST OF MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2019-2035 (USD MILLION) 121
TABLE 96 REST OF MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, FOR APPLICATION, 2019-2035 (USD MILLION) 121
TABLE 97 REST OF MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, BY END USER, 2019-2035 (USD MILLION) 122
TABLE 98 PRODUCT LAUNCH 127
TABLE 99 ACQUISITION 127
TABLE 100 THERMO FISHER SCIENTIFIC INC.: PRODUCT OFFERED 144
TABLE 101 ABBOTT: PRODUCTS OFFERED 149
TABLE 102 MERCK KGAA.: PRODUCTS OFFERED 154
TABLE 104 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 159
TABLE 105 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 163
TABLE 106 GRIFOLS, S.A.: PRODUCT OFFERED 167
TABLE 107 GRIFOLS, S.A.: KEY DEVELOPMENTS 167
TABLE 108 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 172
TABLE 109 WERFEN.: PRODUCTS OFFERED 176
TABLE 111 CARDINAL HEALTH: PRODUCTS OFFERED 184
LIST OF FIGURES
FIGURE 1 GLOBAL IMMUNOHEMATOLOGY MARKET: STRUCTURE 19
FIGURE 2 GLOBAL IMMUNOHEMATOLOGY MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 36
FIGURE 3 GLOBAL IMMUNOHEMATOLOGY MARKET DRIVER: IMPACT ANALYSIS 38
FIGURE 4 PORTER'S FIVE FORCES ANALYSIS: GLOBAL IMMUNOHEMATOLOGY MARKET 43
FIGURE 5 GLOBAL IMMUNOHEMATOLOGY MARKET, PRODUCT SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 46
FIGURE 6 GLOBAL IMMUNOHEMATOLOGY MARKET, BY PRODUCT, 2025 & 2035 (USD MILLION) 47
FIGURE 7 GLOBAL IMMUNOHEMATOLOGY MARKET SHARE (%), BY PRODUCT, 2025 48
FIGURE 8 GLOBAL IMMUNOHEMATOLOGY MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 49
FIGURE 9 GLOBAL IMMUNOHEMATOLOGY MARKET, BY APPLICATION, 2025 & 2035 (USD MILLION) 50
FIGURE 10 GLOBAL IMMUNOHEMATOLOGY MARKETSHARE (%), BY APPLICATION, 2025 50
FIGURE 11 GLOBAL IMMUNOHEMATOLOGY MARKET, END USER SEGMENT ATTRACTIVENESS, 2025 & 2035 (USD MILLION) 54
FIGURE 12 GLOBAL IMMUNOHEMATOLOGY MARKET, BY END USER, 2025 & 2035 (USD MILLION) 55
FIGURE 13 GLOBAL IMMUNOHEMATOLOGY MARKET SHARE (%), BY END USER, 2025 55
FIGURE 14 GLOBAL IMMUNOHEMATOLOGY MARKET, BY REGION, 2025 & 2035 (USD MILLION) 56
FIGURE 15 GLOBAL IMMUNOHEMATOLOGY MARKET SHARE (%), BY REGION, 2025 57
FIGURE 16 NORTH AMERICA MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 58
FIGURE 17 NORTH AMERICA IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 59
FIGURE 18 NORTH AMERICA IMMUNOHEMATOLOGY MARKET SHARE (%), BY COUNTRY, 2025 59
FIGURE 19 EUROPE MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 65
FIGURE 20 EUROPE MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 65
FIGURE 21 EUROPE IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 66
FIGURE 22 ASIA-PACIFIC MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 82
FIGURE 23 ASIA PACIFIC MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 82
FIGURE 24 ASIA PACIFIC IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 83
FIGURE 25 SOUTH AMERICA MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 101
FIGURE 26 SOUTH AMERICA MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 101
FIGURE 27 SOUTH AMERICA IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 102
FIGURE 28 MIDDLE EAST & AFRICA MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 113
FIGURE 29 MIDDLE EAST AND AFRICA MARKET ANALYSIS: IMMUNOHEMATOLOGY MARKET, 2019-2035 (USD MILLION) 113
FIGURE 30 MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET, BY COUNTRY, 2025 & 2035 (USD MILLION) 114
FIGURE 31 COMPETITOR DASHBOARD: GLOBAL IMMUNOHEMATOLOGY MARKET 125
FIGURE 32 U.S. IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 130
FIGURE 33 CANADA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 130
FIGURE 34 GERMANY IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 131
FIGURE 35 UK IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 131
FIGURE 36 FRANCE IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 132
FIGURE 37 ITALY IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 132
FIGURE 38 SPAIN IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 133
FIGURE 39 NETHERLANDS IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 133
Copyright © 2026 Market Research Future 14
FIGURE 40 REST OF EUROPE IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 134
FIGURE 41 CHINA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 134
FIGURE 42 INDIA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 135
FIGURE 43 JAPAN IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 135
FIGURE 44 SOUTH KOREA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 136
FIGURE 45 MALAYSIA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 136
FIGURE 46 THAILAND IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 137
FIGURE 47 INDONESIA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 137
FIGURE 48 REST OF ASIA PACIFIC IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 138
FIGURE 49 BRAZIL IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 138
FIGURE 50 MEXICO IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 139
FIGURE 51 ARGENTINA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 139
FIGURE 52 REST OF SOUTH AMERICA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 140
FIGURE 53 GCC COUNTRIES IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 140
FIGURE 54 SOUTH AFRICA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 141
FIGURE 55 REST OF MIDDLE EAST AND AFRICA IMMUNOHEMATOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2025 141
FIGURE 56 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 143
FIGURE 57 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 145
FIGURE 58 ABBOTT.: FINANCIAL OVERVIEW SNAPSHOT 148
FIGURE 59 ABBOTT: SWOT ANALYSIS 150
FIGURE 60 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT 153
FIGURE 61 MERCK KGAA: SWOT ANALYSIS 155
FIGURE 62 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 158
FIGURE 63 SIEMENS HEALTHINEERS AG: FINANCIAL OVERVIEW SNAPSHOT 162
FIGURE 64 GRIFOLS, S.A.: FINANCIAL OVERVIEW SNAPSHOT 166
FIGURE 65 GRIFOLS, S.A.: SWOT ANALYSIS 168
FIGURE 66 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 171
FIGURE 67 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 173
FIGURE 68 DANAHER CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 179
FIGURE 69 CARDINAL HEALTH: FINANCIAL OVERVIEW SNAPSHOT 183
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們